<DOC>
	<DOCNO>NCT01166204</DOCNO>
	<brief_summary>Our group show increase radiation dose pre-specified normal tissue dose constraint could lead increase TCP NTCP patient non-concurrent concurrent chemo-radiation . Here , investigator want investigate efficacy prospective study patient stage I-III NSCLC , select high-dose radiotherapy without chemotherapy , treat IMRT . The latter technique become standard , patterns recurrence possibility dose-escalation individualise set never investigate properly .</brief_summary>
	<brief_title>Concurrent Non-concurrent Chemo-radiotherapy Radiotherapy Alone With Intensity-modulated Radiotherapy ( IMRT ) Non Small Cell Lung Cancer ( NSCLC ) Individualised Mean Lung Dose ( MLD )</brief_title>
	<detailed_description>Eligible patient ( see ) receive radiotherapy primary tumor initially involve mediastinal lymph node MLD ( Mean Lung Dose ) 20 +/-1Gy , irrespective lung function . Other dose-constraints : spinal cord max : 54Gy , brachial plexus ( Dmax ) :66Gy In concurrence chemotherapy , radiotherapy deliver follow : - First three weeks/30 fraction : twice-daily fraction 1.5Gy , 8h 10h interfraction interval , 5 day per week . Total dose : 45Gy/30 fraction - Thereafter : daily fraction 2.0Gy , 5 day per week target dose reach . In sequential radiotherapy alone schedule , twice-daily 1.8Gy interfraction interval least 8h deliver . The radiation dose specify accord ICRU 50 . Lung density correction apply , well standard QA procedure . Technical requirement standard practice MAASTRO clinic Chemotherapy schedule allow : 1 . 1-2 cycle induction chemotherapy : third generation schedule allow . The type register . 2 . Concurrent part : ( day 1 = first day radiotherapy ) - cisplatin - vinorelbine - cisplatin - docetaxel - cisplatin - etoposide - cisplatin - pemetrexed non-squamous histology Q 3 week ; 3 cycle When calculate creatinin clearance less 60ml/min , cisplatin may substitute carboplatin</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological proven NSCLC IUCC stage IIII , solitary metastasis ( &lt; 6 ) , amendable radical local treatment . Performance status 02 IMRT technique Not NSCLC mixed NSCLC histology ( e.g . small cell carcinoma ) Stage IV , except solitary ( &lt; 6 ) metastasis Performance status 3 No IMRT technique</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>NSCLC</keyword>
</DOC>